Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA 2025-08-26T07:35:25-07:00July 21st, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research 2025-12-19T18:08:11-08:00June 2nd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan 2025-12-29T12:29:29-08:00May 25th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay 2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China 2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan) 2023-02-01T21:02:16-08:00February 1st, 2023|2023 Press Releases, Press Releases| Read more